Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica RemediaLTS:0M8I 61 Debt-to-Equity is 0.01 as of Jun. 2026, which is 50% below its 10-year median of 0.02. GuruFocus rates LTS:0M8I with a GF Score™ of 61/100 and a GF Value™ of lei0.24. The stock has 11 warning signs investors should review. Among 103 Medical Distribution companies, Farmaceutica Remedia ranks better than 99.03% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Farmaceutica Remedia's Debt-to-Equity or its related term are showing as below:
LTS:0M8I'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.37
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Farmaceutica Remedia was 0.37. The lowest was 0.00. And the median was 0.02.
LTS:0M8I's Debt-to-Equity is ranked better than 99.03% of 103
companies
in the Medical Distribution industry
Industry Median: 0.46
vs LTS:0M8I: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Farmaceutica Remedia Debt-to-Equity Related Terms
Farmaceutica Remedia Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M8I vs MCK, COR, CAH: Debt-to-Equity Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia (LTS:0M8I) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Farmaceutica Remedia and its competitors. This is 50% below median its historical median of 0.02. According to the industry distribution chart, Farmaceutica Remedia ranks #1 out of 103 companies in the Medical Distribution industry, placing it in the top 1%.
Is Farmaceutica Remedia's Debt-to-Equity too high?
Farmaceutica Remedia's current Debt-to-Equity of 0.01 is 50% below median its 10-year median of 0.02. The Medical Distribution industry median Debt-to-Equity is 0.46. Farmaceutica Remedia's value of 0.01 is 97.8% below this industry median. Based on the distribution chart, Farmaceutica Remedia ranks #1 out of 103 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Farmaceutica Remedia has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #1 out of 103 companies for Debt-to-Equity. This places Farmaceutica Remedia in the top 1% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.46. Farmaceutica Remedia's value of 0.01 is 97.8% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.46, Farmaceutica Remedia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.46, based on 103 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmaceutica Remedia's current Debt-to-Equity of 0.01 is 97.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current Debt-to-Equity is 0.01, which is 50% below median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Farmaceutica Remedia (LTS:0M8I) has a current Debt-to-Equity of 0.01. The stock's GF Value™ is lei0.24, compared to a current price of lei0.25 — trading 4.2% above its estimated fair value. The current Debt-to-Equity is 0.01, which is 50% below median its 10-year median of 0.02 and 97.8% below the Medical Distribution industry median of 0.46. Farmaceutica Remedia's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Farmaceutica Remedia (LTS:0M8I), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (LTS:0M8I) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.25 is trading 4.2% above its estimated GF Value™ of lei0.24.
Key valuation signals for LTS:0M8I:
Debt-to-Equity: 0.01 (50% below median its 10-year median of 0.02)
GF Value™: lei0.24 vs. price of lei0.25 (4.2% above fair value)
Industry Position: 97.8% below the Medical Distribution median (#1 of 103)
No single metric tells the full story. See the LTS:0M8I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
61GF Score
Get the complete analysis for LTS:0M8I
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M8I has been successfully added to your 
